|
BALTIMORE, Md.—January 21, 2013—Traditionally, negative attitudes have been held toward the use of long-acting injectable antipsychotic (LAIA) medications when managing patients with schizophrenia. The presumption that most patients dislike injectable medications can lead to under treatment, inadequate dosing, and premature discontinuation of treatment resulting in poor clinical outcomes.
 Managing Schizophrenia: Exploring Myths and
Realities of Long-Acting Injectable Antipsychotics
This certified CME online publication, designed for hospital- and community-based psychiatrists and psychiatric nurse practitioners, addresses common misperceptions surrounding the use of LAIAs in the management of schizophrenia. Web-enabled audio clips also explore patient case vignettes to provide participants with the opportunity to translate knowledge into practice in several different clinical scenarios.
“More LAIAs have become available recently, and several are in development; therefore, mental health professionals must understand how to effectively utilize these therapies and address barriers associated with their use,” said William A. Mencia, MD, CCMEP, Vice President of Education and Medical Affairs at Med-IQ.
This activity also focuses on strategies to overcome both physician- and patient-related barriers to the initiation of LAIAs and provides ways for participants to successfully implement the use of LAIAs into their practice.
| Faculty |
| |
Peter J. Weiden, MD
Professor of Psychiatry
Department of Psychiatry
University of Illinois at Chicago
Chicago, IL
|
|
| |
Mark Olfson, MD, MPH
Professor of Clinical Psychiatry
College of Physicians and Surgeons of Columbia University
Research Psychiatrist II
New York State Psychiatric Institute
New York, NY
|
|
Interested clinicians are invited to learn more by visiting www.Med-IQ.com/a692.
This activity has been approved for AMA PRA Category 1 Credit™
Co-sponsored by Columbia University College of Physicians and Surgeons and Med-IQ®.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
© 2013 Columbia University and Med-IQ®. All rights reserved.
For more information, call (toll-free) 866 858 7434, e-mail info@med-iq.com, or visit www.Med-IQ.com/a692.
|
About Med-IQ
Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.
Med-IQ, a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives, has been recognized by the Alliance for Continuing Education in the Health Professions for our excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, connect with us on LinkedIn, and visit our YouTube channel.
For more information, contact: |
close
